Lakefront Biotherapeutics
LKFT
30.00
+0.68
+2.32%
Lakefront Biotherapeutics
US · LKFT
#2803 by market cap
Listed 1970
30.00
+0.68
+2.32%
Live - 5344 symbols - heartbeat 566s ago
· 2026-10-08 07:40
Pre-market
29.50
-1.67%
After-hours
30.00
0.00%
Overnight
29.31
-2.30%
- Market cap
- 1.96B
- P/E (TTM)i
- 2.96
- P/Bi
- 0.54
- EPSi
- 5.45
- Div yieldi
- 0.00%
- 52W posi
- 41%
Reader sentiment
Are you bullish or bearish on LKFT?
Anonymous reader poll. Unscientific, not investment advice.
About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
- Founded
- 1999
- CEO
- Mr. Henry O. Gosebruch
- Employees
- 452
- Headquarters
- Mechelen, Brussels Region, Belgium
- Fiscal year end
- 12-31
- Website
- lakefrontbio.com
Company profile
- Exchange
- US
- Symbol
- LKFT
- Market-cap rank
- #2803
- Listing date
- 1970-01-01
- Market cap
- 1.96B
- Float cap
- 719.38M
- Shares out
- 65.48M
- Float shares
- 23.98M
Sectors & themes
Quote time 2026-10-08 07:40:15 · For reference only, not investment advice and not tailored to your situation.